Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy vs CDK4/6i + ET in HR-low/HER2- Advanced Breast Cancer
NCT06176534Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, capecitabine, vinorelbine in breast cancer, sponsored by Henan Cancer Hospital. Started Jan 2024; status: recruiting.
02
Drugs
paclitaxelcapecitabinevinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06176534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176534.